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adiponectin receptors and nicotinamide adenine
dinucleotide phosphate oxidase in the heart and
aorta in type 2 diabetic rats
Zhixin Guo*, Rong Zhang, Jiawei Li and Guojun XuAbstract
Background: Diabetic cardiovascular disease is associated with decreased adiponectin and increased oxidative
stress. This study investigated the effect of telmisartan on the expression of adiponectin receptor 2 (adipoR2) and
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase subunits in the heart and the expression of
adiponectin receptor 1 (adipoR1) in aorta in type 2 diabetic rats.
Methods: Type 2 diabetes was induced by high-fat and high-sugar diet and intraperitoneal injection of a low dose
of streptozotocin (STZ). Heart function, adipoR2, p22phox, NOX4, glucose transporter 4(GLUT4), monocyte
chemoattractant protein-1(MCP-1) and connective tissue growth factor (CTGF)in the heart, and adipoR1, MCP-1 and
nuclear factor kappa B (NF-κB) in aorta were analyzed in controls and diabetic rats treated with or without
telmisartan (5mg/kg/d) by gavage for 12 weeks.
Results: Heart function, plasma and myocardial adiponectin levels, the expression of myocardial adipoR2 and
GLUT4 were significantly decreased in diabetic rats (P <0.05). The expression of myocardial p22phox, NOX4, MCP-1,
and CTGF was significantly increased in diabetic rats (P <0.05). The expression of adipoR1 was decreased and the
expression of MCP-1 and NF-κB was increased in the abdominal aorta in diabetic rats (P <0.05). Telmisartan
treatment significantly attenuated these changes in diabetic rats (P <0.05).
Conclusions: Our results suggest that telmisartan upregulates the expression of myocardial adiponectin, its
receptor 2 and GLUT4. Simultaneously, it downregulates the expression of myocardial p22phox, NOX4, MCP-1, and
CTGF, contributing so to the improvement of heart function in diabetic rats. Telmisartan also induces a protective
role on the vascular system by upregulating the expression of adipoR1 and downregulating the expression of
MCP-1 and NF-κB in the abdominal aorta in diabetic rats.
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Cardiovascular disease is one of the major complications
of diabetes, resulting in a high percentage of morbidity
and mortality and producing significant costs for the
healthcare system [1]. Increased fatty acid oxidation and
decreased glucose metabolism contribute to the develop-
ment of diabetic cardiomyopathy and can decrease the
ability of the heart to withstand an ischemic insult [2].* Correspondence: zhxguo1966@yahoo.com.cn
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reproduction in any medium, provided the orAdiponectin is an adipocyte-derived protein with anti-
inflammatory, anti-diabetic and anti-atherogenic proper-
ties [3]. Adiponectin is also synthesized and secreted by
human and murine cardiomyocytes. Local production of
adiponectin by cardiomyocytes might have important
functions in the regulation of the cardiac function and/
or metabolism by autocrine and/or paracrine [4].
There are two types of adiponectin receptors, adipo-
nectin receptor type 1 (adipoR1) and adiponectin recep-
tor type 2 (adipoR2). They serve as receptors for
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as well as fatty-acid oxidation and glucose uptake by adi-
ponectin. Adiponectin receptor type 1 and adiponectin
receptor type 2 are not only expressed in skeletal muscle
and liver, but also in heart and kidney [5]. Our previous
study showed that the expression of myocardial adipoR1
was significantly decreased in type 2 diabetic rats [6]. It
is unknown whether the expression of adipoR2 in the
heart and the expression of adipoR1 in aorta are also
changed in type 2 diabetic rat.
Oxidative stress has been suggested to be involved in
the development and progression of diabetes-induced
cardiomyopathy [7]. Activation of nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase seems to be
relevant to the elevated oxidative stress in diabetes [8].
NAD(P)H oxidase consists of membrane-associated sub-
units (gp91phox and p22phox) and cytosolic subunits
(p47phox, p40phox, p67phox and Rac)[9]. Nox4 is one
of homologues of gp91phox/Nox2 [10]. Phagocytic
NADPH oxidase largely depends on regulation by cyto-
solic subunits but not Nox4 for which no cytosolic subu-
nits are required. Nox4 isoform is expressed in a wide
variety of organs, including the heart [11] and is a major
source of oxidative stress in the failing heart [12]. It was
reported that the expression of p22phox and Nox4 in
the heart of diabetic mice and rats [13,14] and the ex-
pression of p47phox in diabetic rat femoral arteries [15]
were significantly increased.
Telmisartan, a unique angiotensin II receptor antag-
onist with selective peroxisome proliferator-activated
receptor gamma(PPARgamma)-modulating activity, func-
tioned as a partial agonist of PPARgamma and achieved
25-30% of maximal receptor activation attained with
conventional PPARgamma ligands [16,17]. Telmisartan
increased plasma adiponectin level in hypertensive
patients with type 2 diabetes [18] and also stimulated
adiponectin protein expression in murine 3T3-L1 adi-
pocytes [19]. Telmisartan normalizes vascular dys-
function and reduces platelet activation in diabetic rats
[20]. Our previous study showed that telmisartan treat-
ment significantly attenuated the decreased expression of
myocardial adipoR1 in diabetic rats [6]. It is unknown
whether the expression of adipoR2 and NADPH oxidase
subunits in the heart and the expression of adipoR1 in
aorta are changed by telmisartane treatment in type 2
diabetic rats.
This study was aimed: 1) to explore the expression of
adipoR2 in the heart and the expression of adipoR1 in
aorta in type 2 diabetic rats induced by high-fat and
high-sugar diet and intraperitoneal injection of a low
dose of streptozotocin (STZ); 2) to investigate the effect
of telmisartan on the expression of adipoR2 and
NADPH oxidase subunits in the heart and the expres-
sion of adipoR1 in aorta in type 2 diabetic rats.Materials and methods
Induction of diabetes
Thirty-six male Wistar rats weighing 140-180g, pur-
chased from Physiological Laboratory of Shanxi Medical
University (Taiyuan, Shanxi, China), were used in the
study. All rats were housed in a temperature-controlled
room (22-24oC) and kept on a 12 hour light/dark cycle.
All animals received humane care in accordance with
the principles of the Chinese Council on Animal Care.
After two week’s adaptation, all rats were randomly
divided into 2 groups: control (C, n = 10) and diabetic
(n = 26). Control rats were fed with standard rat chow.
Diabetic rats were fed with high-fat chow (ingredients:
10% refined lard, 20% sucrose, 2% cholesterol, 1% so-
dium cholate and 67% common food), which were pro-
vided by Animal Experimental Centre of Shanxi Medical
University. Four weeks later, diabetic rats were given the
peritoneal injection of a low dose of streptozotocin (30
mg/kg body weight; Sigma, St. Louis, MO, USA) [21],
while the control group was given equivalent volume of
citric acid buffer. After one week of STZ injection, fast-
ing plasma glucose (FPG) was tested and the rats with
FPG ≥7.8 mmol/L and insulin resistance were consid-
ered to be diabetic (n= 20) [21]. Diabetic rats were again
randomly divided into diabetic (D, n = 10) and diabetic
treated (DT, n = 10). Telmisartan (5mg/kg/d, Boehringer
Ingelheim pharmaceutical company, Germany) [22] was
administrated to diabetic treated rats by gavage for 12
weeks. The equivalent volume of normal sodium was
administrated to control and diabetic rats by gavage for
12 weeks. Subsequently, blood samples were collected
every 2 weeks. Blood was centrifuged at 10,000 g for 45
minutes, plasma was collected and plasma glucose levels
were measured. At termination, 1 day before the experi-
ments were finished, all animals were fasted for 12-14 h
and then were anesthetized with an intraperitoneal injec-
tion of 10% chloral hydrate (0.3mL/100g body weight).
The maximum descent-speed of pressure in isovolu-
metric relaxation period in the left ventricle (-dp/dtmax)
and the maximum ascendent-speed of pressure in isovo-
lumic contraction period in the left ventricle (+dp/
dtmax) were measured by carotid artery cannula. The
rats were sacrificed after blood sample had been with-
drawn from abdominal cardinal vein. The blood sample
was centrifuged and plasma aliquots were stored at
–80°C until assays were done. The heart was immedi-
ately taken out of thoracic cavity and the abdominal
aorta was immediately taken out of abdominal cavity
after the rat was sacrificed. The heart and the abdom-
inal aorta were rinsed with normal sodium and dried
by filter-paper and then the heart was weighed. The
ratio of heart weight to body weight was calculated.
The apex of heart and a part of abdominal aorta were
fixed in 10% neutral buffered formalin and processed
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and abdominal aorta were immediately thrown into the
liquid nitrogen and then stored in the -70°C refrigerator
until analyses were carried out.Measurement of cardiac function
Following anesthesia with an intraperitoneal injection of
10% chloral hydrate (0.3ml/100g), the neck skin was cut
open and the right common carotid artery was fully
exposed. A micromanometer-tipped catheter was inserted
into the left ventricle through the right common carotid ar-
tery for measurement of left ventricular pressure. Left ven-
tricular end-diastolic pressure (LVEDP) and the maximal
rate of rise and decline of ventricular pressure (±dp/dt
[max]) were obtained by BL-410 Bio-signal analysis system
(Chengdu TME Technology Co., Ltd, Sichuan, China).Plasma analytical procedures
The plasma glucose level was measured by the glucose
oxidase method using an autoanalyzer (Beckman Instru-
ments, USA). Plasma cholesterol, triglyceride and free
fatty acid were measured colorimetrically by using com-
mercially available kit (SiRuiKe Biotechnology Co., Ltd,
Shanghai, China). Plasma adiponectin was measured by
using a commercially available ELISA kit (Westang Bio-
technology Co., Ltd, Shanghai, China). Plasma insulin
was measured by using a commercially available radio-
immunoassay kit (China Institute of Atomic Energy,
Beijing, China). Insulin sensitivity index (ISI) was cal-
culated as the following formula: ISI ¼ In 1FPGFINSð Þ
h i
.Determination of cardiac adiponectin
Frozen heart tissue was pulverized and homogenized
at 4°C in cold buffer (20 mM Tris-HCl, pH 7.5, 50
mM 2-mercaptoethanol, 5 mM EGTA, 2 mM EDTA, 1
mM PMSF, 10 mM NaF, 25 μg/ml leupeptin, 2 μg/ml
aprotinin) and then centrifuged at 1500 g for 5 min-
utes at 4°C. The supernatant was collected and stored
at –80°C until analyses were conducted. The protein
content of the samples was measured using the Brad-
ford protein assay [23] with the use of bovine serum
albumin as a standard. Cardiac adiponectin was mea-
sured using a commercially available enzyme-linked
immunosorbent assay (ELISA) kit (Westang Biotech-
nology Co., Ltd, Shanghai, China).Morphologic study
Tissues fixed in 10% buffered formalin were embedded
in paraffin, sectioned at 4 μm and stained with
hematoxylin and eosin (HE) and Masson’s trichrome for
light microscopic morphologic study.Immunohistochemical analysis of adipoR1, adipoR2,
CTGF, MCP-1 and NF-κB
Ventricular samples and abdominal aorta were immedi-
ately fixed in 10% neutral buffered formalin overnight
and embedded in paraffin. Paraffin embedded tissue
blocks were sectioned at 3 μm and sections were
mounted on positively charged slides. The slides were
deparaffinized, rehydrated, blocked with 3% hydrogen
peroxide [to block endogenous peroxidase activity,
washed with phosphate-buffered saline (PBS)], and
blocked with 5% normal goat serum in PBS for 30 min.
The slides were subsequently incubated with primary
rabbit polyclonal adiponectin receptor type 1 (1:200)
and type 2 (1:400) antibody (Beijing Biosynthesis Bio-
technology Co., Ltd, Beijing, China), connective tissue
growth factor antibody (1:100, Wuhan Boster Bio-
logical Engineering Company Limited, Hubei, China ),
MCP-1 antibody (1:100,Beijing Biosynthesis Biotechnol-
ogy Co., Ltd, Beijing, China) and NF-κB antibody(1:50,
Zhongshan Goldenbridge Biotechnology Co., Ltd, Bei-
jing, China)in PBS containing 1% normal goat serum
overnight at 4°C. The primary antibody was rinsed off
with PBS, and the sections were incubated with biotin
labeling goat anti-rabbit secondary antibodies (1:100,
Zhongshan Goldenbridge Biotechnology Co., Ltd, Bei-
jing, China) for 30 min. After three washing steps in
PBS were completed, the sections were stained using
horseradish enzyme labeling strepto-avidin solution
(1:100, Zhongshan Goldenbridge Biotechnology Co.,
Ltd, Beijing, China) for 10 min, washed with PBS,
coloured with 3, 3′-diaminobenzidine (DAB), and
washed with distilled water. The sections were coun-
terstained using hematoxylin, washed in running water,
dehydrated in increasing grades of alcohol, and cleared
in xylene before being mounted in resinous mounting
medium with coverslips. Some sections incubated with
nonspecific rabbit immunoglobulins (IgG) served as
negative controls. Quantification was performed with
the observer blinded to details. With the use of high
power microscope, all slides were observed and photo-
graphed. The average of five fields under microscope
(×400) in each slice were randomly selected, and the
positive stained intensity or the average value of gray
scale which had an inverse proportion to the positive
stained intensity was quantified by using BI-2000 color
image processing system (Chengdu TME Technology
Co., Ltd, Sichuan, China).
Semi-quantitative reverse transcription-PCR (RT-PCR)
analysis for adipoR, MCP-1 and GLUT4
Total RNA extraction was performed using Trizol
reagent (Invitrogen, Carlsbad, California, USA) accord-
ing to the manufacturer’s recommendations. Primer
sequences were described in Table 1. The PCR reaction
Table 1 Primers used in semi-quantitative reverse
transcription-PCR
















Table 2 Primers used in real-time fluorescence
quantitative PCR
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for denaturation at 94°C for 20 seconds, annealing at
54-56°C for 30 seconds, and extension at 72°C for
30 seconds, terminated after a 10-minute extension at
72°C. Ten microliters of each PCR reaction mixture were
electrophoresed in a 1.5% agarose gel and bands were
visualized by ethidium bromide staining. The density of
the DNA bands of the PCR products was analyzed by
using the software (Tianjin DiDe Technology Co., Ltd,
Tianjin, China).
Real-time fluorescence quantitative PCR analysis for
p22phox and NOX4
Extracted RNA and synthesized cDNA were described
above. Real-time quantitative polymerase chain reaction
was performed with 50 μl reaction volumes containing
25μl 2× FastStart Universal SYBR Green Master Mix
(Roche Ltd., Basel, Switzerland), 1μl 0.3 μM of each pri-
mer, 5 μl of cDNA template, and 19 μl deionized water.
Primer sequences are described in Table 2. PCR amplifi-
cations were done on a real-time fluorescence quantita-
tive PCR detection system (Xi’an Tianlong Science and
Technology Co., Ltd,Xi’an, China) using the following
parameters: initial denaturation of 95°C for 10 min, fol-
lowed by 40 cycles for denaturation at 94°C for 30 sec-
onds, annealing at 58°C for 30 seconds, and extension at
72°C for 45 seconds. Relative gene expression levels were
quantified using the comparative ΔCt (cycle threshold)
method. This method normalized Ct values of the
detected gene to the average of that of the housekeeping
genes and calculated the relative expression values as
fold changes of the control. Ct values were extractedusing the software. Data analysis was performed using
the 2-ΔΔCt method [24].
Statistical analysis
Data are expressed as mean ± S.E.M. Statistical analysis
was performed by one –way ANOVA followed by




Plasma glucose levels were significantly increased in dia-
betic rats compared to controls. Telmisartan treatment
slightly but significantly reduced the plasma glucose level
in diabetic rats. The levels of plasma insulin, total choles-
terol, triglycerides and free fatty acid were significantly
increased in diabetic rats compared to controls and tel-
misartan treatment prevented these changes in diabetic
rats. Insulin sensitivity index (ISI) were significantly
reduced in diabetic rats compared to controls and telmi-
sartan treatment significantly increased the insulin sensi-
tivity index in diabetic rats. The ratio of heart weight to
body weight, an index of cardiac hypertrophy, was sig-
nificantly increased in diabetic rats compared to controls
and telmisartan treatment significantly decreased the
ratio of heart weight to body weight in diabetic rats (See
table one in reference [6], a paper we previously pub-
lished. The samples we used in this paper were the same
as in reference [6]).
Histological changes
The results of the myocardium stained by Masson’s tri-
chrome and observed through the light microscope were
as following: The myocardial cells lined up in order, the
spherical or oval cellular nucleus was in the same size
and was stained dark and in uniformity, and the cyto-
plasm was stained red and in uniformity in control rats.
The myocardial cells lined up in disorder, the cellular
nucleus was in irregular size, breakdown and lost, the
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was unclear, and collagen fiber was increased in diabetic
rats. The pathological changes were obviously improved
in diabetic rats treated with telmisartan. The myocardial
collagen content was increased in diabetic rats and was
decreased in diabetic rats treated with telmisartan
(Figure 1).
The results of the aorta stained by hematoxylin and
eosin (HE) and observed through the light microscope
were as following: the intima of aorta was smooth, all
level cells lined up in order, endothelial cells were appla-
nate and clung to the smooth and straight internal elastic
lamina, and medial elastic lamina lined up in parallel
with smooth muscle cell orderly and alternately in con-
trol rats. Endothelial cells were broken off and the shal-
low smooth muscle cells in medial elastic lamina were
proliferated and lined up in disorder in diabetic rats. The
pathological changes of aorta were obviously improved in
diabetic rats treated with telmisartan (Figure 2).Heart function
Compared to controls, +dp/dtmax and -dp/dtmax were
significantly reduced and LVEDP was significantly
increased in diabetic rats, indicating that the heart func-
tion was significantly decreased in diabetic rats. Telmi-
sartan treatment attenuated these changes in diabetic
rats (See table two in reference [6], a paper we previ-
ously published. The samples we used in this paper were



















Figure 1 Top panel: representative slides showing Masson's trichrom
arrow) in the myocardium. Slides A, B, C represent control, diabetic and
Bottom: bar graph shows quantitative analysis of myocardial collagen cont
Control (C), diabetic (D), diabetic treated (DT). Data are expressed as mean
different from diabetic.Immunohistochemical assay
The yellow positive staining of adipoR2 was mainly
located in myocardial cellular member and cytoplasm.
The adipoR2 expression was quantified using the aver-
age value of gray scale which had an inverse proportion
to the positive stained intensity. The average value of
gray scale of adipoR2 was significantly increased in the
heart in diabetic rats compared to controls, indicating
that the positive stained intensity of adipoR2 was sig-
nificantly decreased in the heart in diabetic rats com-
pared to controls. Telmisartan treatment significantly
decreased the average value of gray scale of adiponectin
receptor 2 in the heart in diabetic rats, indicating that
telmisartan treatment significantly increased the positive
stained intensity of adipoR2 in the heart in diabetic rats
(Figure 3).
The yellow positive staining of CTGF was mainly
located in myocardial cellular cytoplasm. The integrated
optical density(IOD)of positive staining of CTGF was sig-
nificantly increased in the heart in diabetic rats compared
to controls. Telmisartan treatment significantly decreased
the integrated optical density (IOD) of positive staining of
CTGF in the heart in diabetic rats (Figure 4).
The yellow positive staining of NF-κB was mainly
located in cellular nucleus and the yellow positive staining
of MCP-1 was mainly located in cellular cytoplasm in
abdominal aorta. The integrated optical density (IOD) of
positive staining of NF-κB and MCP-1 was significantly
increased in aorta in diabetic rats compared to con-




e staining (Myocardial collagen stained in blue as shown by
diabetic treated with telmisartan, respectively. Amplifications × 400.
ent in control and diabetic rats treated with or without telmisartan.
± S.E.M (n = 10 per group). * P <0.05 different from control, # P <0.05
CBA
Figure 2 Representative slides showing HE staining in the abdominal aorta of rats. Slides A, B, C represent control, diabetic and diabetic
treated with telmisartan, respectively. Amplifications × 200.
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NF-κB and MCP-1 in aorta in diabetic rats (Figures 5 and 6).
Plasma and myocardial adiponectin levels
Plasma and myocardial adiponectin levels were signifi-
cantly decreased in diabetic rats compared to controls.
Telmisartan treatment significantly increased plasma
and myocardial adiponectin levels in diabetic rats (See
Table two in reference [6], a paper we previously pub-
lished. The samples we used in this paper were the same
as in reference [6]).
Myocardial mRNA expression of adiponectin receptor 2,
GLUT4, MCP-1, NOX4 and p22phox
The mRNA expression of myocardial adiponectin receptor




























Figure 3 Top panel: representative slides showing immunohistochem
the myocardium. Slides A, B, C represent control, diabetic and diabetic tr
graph shows quantitative analysis of myocardial adipoR2 expression in con
expression was quantified using the average value of gray scale which had
diabetic (D), diabetic treated (DT). Data are expressed as mean ± S.E.M (n =
from diabetic.compared to controls. Telmisartan treatment significantly
increased the mRNA expression of myocardial adiponectin
receptor 2 and GLUT4 in diabetic rats (Figures 7 and 8).
The mRNA expression of myocardial MCP-1, NOX4
and p22phox was significantly increased in diabetic rats
compared to controls. Telmisartan treatment significantly
reduced the mRNA expression of myocardial MCP-1,
NOX4 and p22phox in diabetic rats (Figures 9, 10 and 11).The mRNA expression of adiponectin receptor 1 in
abdominal aorta
The mRNA expression of adiponectin receptor 1 in ab-
dominal aorta was significantly reduced in diabetic rats
compared to controls. Telmisartan treatment significantly
increased the mRNA expression of adiponectin receptor




ical staining of AdipoR2 (stained in brown as shown by arrow) in
eated with telmisartan, respectively. Amplifications × 400. Bottom: bar
trol and diabetic rats treated with or without telmisartan. The adipoR2
an inverse proportion to the positive stained intensity. Control (C),

































A B C 
Figure 4 Top panel: representative slides showing immunohistochemical staining of CTGF (stained in brown as shown by arrow) in the
myocardium. Slides A, B, C represent control, diabetic and diabetic treated with telmisartan, respectively. Amplifications × 400. Bottom: bar graph
shows quantitative analysis of myocardial CTGF expression in control and diabetic rats treated with or without telmisartan. Control (C), diabetic (D),
diabetic treated (DT). Data are expressed as mean ± S.E.M (n = 10 per group). * P <0.05 different from control, # P <0.05 different from diabetic.
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This study showed that diabetic rat hearts exhibited
increased expression of CTGF and collagen content with
concomitant cardiac hypertrophy and fibrosis. Plasma and


































Figure 5 Top panel: representative slides showing immunohistochemic
abdominal aorta. Slides A, B, C represent control, diabetic and diabetic trea
shows quantitative analysis of NF-κB expression in aorta in control and diabe
diabetic treated (DT). Data are expressed as mean ± S.E.M (n= 10 per group)adipoR2 in heart, and the mRNA expression of adipoR1 in
aorta were decreased in type 2 diabetic rats. The myocardial
mRNA expression of NADPH oxidase subunits, p22phox
and Nox4, was increased in type 2 diabetic rats. Telmisar-
tan treatment prevented these changes in diabetic rats.CB
DT
#
al staining of NF-κB (stained in brown as shown by arrow) in
ted with telmisartan, respectively. Amplifications× 200. Bottom: bar graph
tic rats treated with or without telmisartan. Control (C), diabetic (D),



































Figure 6 Top panel: representative slides showing immunohistochemical staining of MCP-1 (stained in brown as shown by arrow) in
abdominal aorta. Slides A, B, C represent control, diabetic and diabetic treated with telmisartan, respectively. Amplifications × 200. Bottom: bar
graph shows quantitative analysis of MCP-1 expression in aorta in control and diabetic rats treated with or without telmisartan. Control (C),
diabetic (D), diabetic treated (DT). Data are expressed as mean ± S.E.M (n = 10 per group). * P <0.05 different from control, # P <0.05 different
from diabetic.
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receptors in the heart and aorta in type 2 diabetic rats
Adiponectin exerts its effect through adiponectin recep-
tor 1 and 2, which are both expressed in the heart
in vivo [5] and in the cardiomyocyte in vitro [4]. Adipo-
nectin receptors were also expressed in atherosclerotic









































Figure 7 RT-PCR analysis of myocardial mRNA expression of
adipoR2 in control and diabetic rats treated with or without
telmisartan. Mean band density was normalized relative to GAPDH.
Control (C), diabetic (D), diabetic treated (DT). Data are expressed as
mean ± S.E.M (n = 10 per group). * P <0.05 different from control,
# P <0.05 different from diabetic.[5,25]. Overweight patients with coronary artery disease
had decreased surface expression of adiponectin recep-
tors in peripheral monocytes [26]. Although the protein
expression of adiponectin receptor 1 in coronary arter-
ioles and aortas was similar between control and diabetic
mice, the protein expression of adiponectin receptor 2




































Figure 8 RT-PCR analysis of myocardial mRNA expression of
GLUT4 in control and diabetic rats treated with or without
telmisartan. Mean band density was normalized relative to GAPDH.
Control (C), diabetic (D), diabetic treated (DT). Data are expressed as
mean ± S.E.M (n = 10 per group). * P <0.05 different from control,




































Figure 9 RT-PCR analysis of myocardial mRNA expression of
MCP-1 in control and diabetic rats treated with or without
telmisartan. Mean band density was normalized relative to GAPDH.
Control (C), diabetic (D), diabetic treated (DT). Data are expressed as
mean ± S.E.M (n = 10 per group). * P <0.05 different from control,



































Figure 11 Real-time fluorescence quantitative PCR analysis of
myocardial mRNA expression of p22phox in control and
diabetic rats treated with or without telmisartan. Relative gene
expression levels were normalized relative toβ-actin. Control (C),
diabetic (D), diabetic treated (DT). Data are expressed as mean ± S.E.
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in vascular endothelial cells significantly enhanced the
antiinflammatory effect of adiponectin [28]. Our study
showed that the expression of adipoR2 in the heart and
the expression of adipoR1 in aorta were decreased in
diabetic rats. The decreased adiponectin receptors may
be due to hyperinsulinemia since it has been reported
that insulin deficiency increased, but insulin replenish-
ment decreased the expression of adipoR1/2 in animals
in vivo [29]. The decreased adiponectin and its receptors
may lead to adiponectin resistance, which may limit adi-


































Figure 10 Real-time fluorescence quantitative PCR analysis of
myocardial mRNA expression of NOX4 in control and diabetic
rats treated with or without telmisartan. Relative gene expression
levels were normalized relative toβ-actin. Control (C), diabetic (D),
diabetic treated (DT). Data are expressed as mean ± S.E.M (n = 10
per group). * P <0.05 different from control, # P <0.05 different from
diabetic.protective effect on diabetic heart and aorta. The
decreased adiponectin and its receptors may together
play a role in the occurrence and progression of cardio-
myopathy and atherosclerosis in type 2 diabetic rats.
Adiponectin receptors could be modulated by agonists
of the nuclear receptors PPARalpha, PPARgamma, and
LXR [25]. Our study showed that telmisartan, a unique
angiotensin II receptor antagonist with selective
PPARgamma-modulating activity [16,17], increased the
mRNA expression of AdipoR2 in the heart and the
mRNA expression of AdipoR1 in the aorta in diabetic
rats, indicating that angiotensin II could down-regulate,








































Figure 12 RT-PCR analysis of mRNA expression of adipoR1 in
abdominal aorta in control and diabetic rats treated with or
without telmisartan. Mean band density was normalized relative to
GAPDH. Control (C), diabetic (D), diabetic treated (DT). Data are
expressed as mean ± S.E.M (n = 10 per group). * P <0.05 different
from control, # P <0.05 different from diabetic.
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study are in agreement with the results of studies [25,30]
showing that adiponectin receptors were expressed in
adult ventricular cardiomyocytes, atherosclerotic lesions
and macrophages, and upregulated by activation of per-
oxisome proliferator-activated receptor gamma.
Adiponectin can improve both glucose metabolism
and insulin resistance [31]. Glucose enters the heart via
the facilitative glucose transporters GLUT1 and GLUT4
[32]. Glucose transporter expression in the heart is
altered in various pathological states. Our study showed
that the mRNA expression of GLUT4 was decreased, in-
dicating that glucose metabolism would be reduced in
diabetic rat hearts. It was reported that changes in glu-
cose transporter expression contributed to myocardial
dysfunction in diabetes [33]. In addition, GLUT4-
deficient mice developed striking cardiac hypertrophy
[34]. Normalization of glucose homeostasis by transgenic
re-expression of GLUT4 in the skeletal muscle resulted
in a reversal of the cardiac pathology in mice heterozy-
gous for GLUT4 ablation [35]. Hence, we propose that
the decreased cardiac GLUT4 observed in this study
may contribute to the deterioration in heart function
and to the cardiac hypertrophy seen in diabetic rats. Our
study showed that telmisartan treatment reduces cardiac
hypertrophy, improved the heart function, and increased
myocardial expression of GLUT4 in diabetic rats. The
increased adiponectin and its receptors may partly ex-
plain the increased GLUT4, which may contribute to the
ameliorated heart function in diabetic rats treated with
telmisartan.
Effect of telmisartan on the expression of inflammatory
cytokines in the heart and aorta in type 2 diabetic rats
Heart failure, diabetes, and obesity are recognized as
states of chronic inflammation. Inflammatory cytokines
may play a role in all three of these conditions [36,37].
Monocyte chemotactic protein-1 (MCP-1) has been
shown to be produced and released by the heart and
to be increased in failing heart [38,39]. Increased
levels of MCP-1 are associated with previously un-
known abnormal glucose regulation in patients with
acute ST-elevation myocardial infarction [40]. Our
study showed that cardiac expression of MCP-1 was
increased in diabetic rats. Telmisartan treatment
decreased the cardiac expression of MCP-1 in diabetic
rats. It was reported that adiponectin suppressed MCP-1
production in lipopolysaccharide-treated 3T3-L1 adipo-
cytes [41]. Oxidative stress increased the level of MCP-1
[42]. Therefore, the elevated cardiac MCP-1 may be due
to the decreased adiponectin and the increased oxidative
stress, and may be involved in the diabetic cardiac deteri-
oration. The increased adiponectin and decreased
NADPH oxidase by telmisartan treatment may lead to thedecreased inflammation factor MCP-1 in the heart,
which may result in the improved heart function in dia-
betic rats.
This study showed that the expression of MCP-1 and
NF-κB was increased in aorta in diabetic rats. Telmisar-
tan treatment significantly reduced the expression of
MCP-1 and NF-κB and alleviated the pathological alter-
ation in aorta in diabetic rats, suggesting that telmisartan
may lessen the atherosclerotic degree by downregulating
the expression of MCP-1 and NF-κB in aorta in diabetic
rats. It was reported that adiponectin reduced aortic NF-
kappaB expression in ApoE knockout mice and inhibited
IκBα phosphorylation and nuclear factor κB protein ex-
pression in aorta of type 2 diabetic mice [27,43].
Adenovirus-mediated overexpression of AdipoR signifi-
cantly enhanced the suppressive effect of adiponectin on
NF-kappaB activation in vascular endothelial cells [28].
Therefore, the increased expression of MCP-1 and
NF-κB in aorta may be associated with the reduced
expression of adiponectin and its receptors.
Effect of telmisartan on the expression of NADPH oxidase
in the heart in type 2 diabetic rats
Oxidative stress has been suggested to be involved in the
development and progression of diabetes-induced car-
diomyopathy (7). NADPH oxidase has emerged as the
main source of ROS in the cardiovascular tissues [44]. It
was reported that the expression of NADPH oxidase
subunits, p22phox and Nox4 was significantly increased
in the heart of diabetic mice and rats [13,14,45,46], indi-
cating that Nox4 was an important source of ROS in the
left ventricle and Nox4-derived ROS contribute to car-
diomyopathy at early stages of type 1 diabetes [45]. Con-
sistent with these studies, the present study also showed
that the expression of myocardial p22phox and Nox4
was significantly increased in type 2 diabetic rats, sug-
gesting that NADPH oxidase might play a crucial role in
the development of diabetic cardiomyopathy. It was
reported that telmisartan treatment reduced the protein
expression of renal and vascular NADPH oxidase subu-
nits in diabetic mice and cardiac NADPH oxidase activ-
ity in diabetic rats [47,48]. Our study showed that
telmisartan treatment decreased the myocardial mRNA
expression of NADPH oxidase subunits, p22phox and
Nox4, which may result in the reduced oxidative stress
and the improved heart function, in diabetic rats.
Conclusions
In summary, this study demonstrates that diabetic rat
hearts exhibit increased expression of CTGF and colla-
gen content accompanied by cardiac hypertrophy and in
creased fibrosis. The plasma and myocardial adiponectin
levels and the mRNA expression of myocardial adipoR2
are decreased, which may lead to the decrease in cardiac
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rats. The cardiac mRNA expression of p22phox and
NOX4 is significantly increased, indicating that oxidative
stress is increased in the heart in diabetic rats. The
decreased mRNA expression of adipoR1 may lead to the
increased expression of MCP-1 and NF-κB in aorta in
diabetic rats. Telmisartan up-regulates the expression of
myocardial adiponectin and its receptor 2 and GLUT4,
down-regulates the expression of myocardial p22phox,
NOX4, MCP-1, and CTGF, which may contribute to the
improvement of heart function in diabetic rats. Telmi-
sartan may also produce the protective role on the vas-
cular by upregulating the expression of adipiR1 and
downregulating the expression of MCP-1 and NF-κB in
the abdominal aorta in diabetic rats.
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